Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.

Details

Language :

English

ISSN :

15384047

Volume :

12

Issue :

5

Database :

Complementary Index

Journal :

Cancer Biology & Therapy

Publication Type :

Academic Journal

Accession number :

65319850

Full Text :

https://doi.org/10.4161/cbt.12.5.16394